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Cholinergic syndrome is a common topic at western medical universities yet rarely observed in clinical practice. The 
treatment involves muscarinic antagonists, acetylcholinesterase reactivation, seizure control, and supportive measures. 
Here we report a case of a 52-year old Caucasian male who attempted suicide by ingesting a purple crystal powder that 
turned out to be a mixture of carbofuran and chlormephos. At clinical examination, the patient presented with salivation, 
perspiration, diarrhoea, bradypnoea, loss of consciousness, and epileptic seizures. Laboratory tests showed low plasma 
cholinesterase, and we started obidoxime along with supportive intensive care treatment. He was later transferred to the 
psychiatry department for further diagnostics and treatment.
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Organophosphates (OPs) are pesticides that inhibit 
acetylcholinesterase (AChE) in synapses with irreversible 
binding, which causes accumulation of acetylcholine (ACh) 
and overstimulation of nicotinic and muscarinic cholinergic 
receptors (1–3). This can be measured with the erythrocyte 
ACh assay, which is not readily available in all laboratories. 
An alternative marker for diagnosis is plasma cholinesterase 
(ChE), also known as butyrylcholinesterase (BuChE), 
which is produced by the liver and has a drawback of not 
accurately reflecting the severity of poisoning (1, 4). It 
circulates in the blood and does not have any known 
physiological function (5). Carbamates are similar 
compounds that cause a transient AChE inhibition, which 
lasts about 48 h (2).
OPs can cause cholinergic toxidrome, intermediate 
syndrome, OP-induced delayed polyneuropathy, and 
chronic OP-induced neuropsychiatric disorder (5). This 
case report will focus mainly on acute manifestations of 
cholinergic syndrome. Severe muscarinic cholinergic 
symptoms are easily remembered from textbooks by two 
mnemonics: SLUDGE/BBB (salivation, lacrimation, 
urination, diaphoresis, gastro-intestinal upset, emesis, 
bronchorrhoea, bronchospasm, bradycardia) and/or 
DUMBBBELS (d iar rhoea ,  u r ina t ion ,  myos is , 
bronchorrhoea/bronchospasm/bradycardia, emesis, 
lacrimation, salivation). Additionally, an exposed person 
might experience fasciculation, muscle weakness, paralysis, 
acute lung injury, central nervous system (CNS) depression, 
agitation, confusion, seizures, and coma (1, 2, 5, 6). 
Hypotension, ventricular dysrhythmias, metabolic acidosis, 
pancreatitis, and hyperglycaemia may also develop. As 
acute effects of OP poisoning are well known, several recent 
studies have shifted focus on its chronic effects and 
additional OP and carbamate targets such as oxidative stress, 
axonal transport deficits, neuroinflammation, and 
autoimmunity, the knowledge of which could provide new 
treatment possibilities (7, 8).
Treatment of acute poisoning usually involves 
resuscitation, decontamination, symptomatic and supportive 
treatment, including oxygen supplementation, extracorporeal 
cardiopulmonary support, and early seizure control. Specific 
antidotes used in OP poisoning are muscarinic antagonists 
(e. g. atropine) and oximes as AChE reactivators (1, 4, 6), 
If hospital supplies of atropine are limited or CNS 
anticholinergic toxicity is present before adequate symptom 
control is achieved, glycopyrrolate can be given, and if 
respiratory symptoms are the main problem, ipratropium 
inhalations can also be administered (6). The use of 
antioxidants is still a controversy, as some animal and 
human studies report no substantial benefits against OP 
poisoning, while others do for several substances (7–10).
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A 52-year old Caucasian male, previously treated for 
alcohol abuse, otherwise healthy, was admitted to the 
intensive care unit due to bradypnoea. He was found having 
an epileptic seizure by a local doctor, who administered 
10 mg of diazepam, which stopped the seizures. When the 
emergency doctor arrived, the patient was unconscious, 
bradypnoic (6 breaths/min), and cyanotic (SpO2 without 
supplemental oxygen at 60 %). He underwent rapid 
sequence intubation with etomidate, rocuronium, fentanyl, 
and midazolam. During transport to the hospital the patient 
had narrow pupils and salivated excessively. In the 
emergency department he underwent head CT and chest 
X-ray, which did not detect abnormalities.
Upon admission to the intensive care unit (ICU), 
approximately 2 h after the seizure, we additionally 
observed excessive perspiration and diarrhoea but no other 
signs of excessive muscarinic stimulation such as urinary 
incontinence, nausea, vomiting, bronchospasm, or 
bronchorrhoea). The patient was haemodynamically 
stabilised after fluid resuscitation and did not need any 
vasopressor or inotropic support.
Initial laboratory tests revealed leucocytosis (17.5/
mm3), hyperglycaemia (14 mmol/L), high creatine kinase 
(10.29 µkat/L), hyperlactataemia (3.0 mmol/L), and 
hypokalaemia (2.96 mmol/L). The patient was acidotic 
(pH 7.08), with bicarbonate level of 23.7 mmol/L, pCO2 of 
11.2 kPa, and pO2 of 15.5 kPa. In addition, serum ChE was 
low (32 µkat/L).
Basic urine tox screen for opiates, amphetamines, 
cocaine, cannabis, and methadone was negative and so was 
serum alcohol. Table 1 shows relevant laboratory findings 
and how they changed over the first three days at ICU.
The patient was treated empirically with amoxicillin 
and clavulanic acid for possible aspiration pneumonia. 
Serratia marcescens, Escherichia coli, and Haemophilus 
influenzae were isolated from tracheal aspiration, and the 
antibiotic was continued following the antibiogram. Due 
to suspected poisoning with cholinergic substances, we 
consulted the national Poison Control Centre in Ljubljana, 
Slovenia and sent urine and gastric lavage fluid samples to 
the Institute for Forensic Medicine, Ljubljana, where they 
identified carbofuran in urine and a combination of 
carbofuran and chlormephos in the gastric fluid. In addition, 
the patient’s relatives brought a bag of purple crystal powder 
they found at home next to ground coffee, which contained 
the same substances found in the gastric fluid. They did not 
know how much was ingested but thought that he could 
have drunk it with his morning coffee.
We began treatment with obidoxime intravenously (iv) 
approximately 10 h after admission. Initially, we 
administered a 250 mg bolus, which was followed by a 
continuous infusion of 750 mg diluted in 500 mL of 0.9 % 
sodium chloride (NaCl) solution that lasted 24 h. The patient 
continued to receive standard intensive care medication: 
analgesics, sedatives, prophylactic low-molecular weight 
heparin, proton pump inhibitors, and balanced iv fluids. He 
also received thiamine parenterally due to history of alcohol 
abuse.
In the first eight hours at ICU, he experienced additional 
short-term epileptic seizures, which were managed with 
lorazepam. We do not believe the patient has had any other 
indications or conditions that could provoke seizures other 
than poisoning. No further seizures developed after 
administration of obidoxime. EEG showed abnormal 
readings due to badly defined, irregular, and distinctly 
slowed baseline activity. It also showed some bursts of slow 
delta waves over the frontal, frontotemporal, and 
frontocentral brain regions. A neurologist was consulted, 
who concluded that the seizures were due to metabolic 
causes, so no further imaging was done.
After five days, a psychiatrist was consulted, who 
reported symptoms of depression and possibility of suicide 
attempt, which the patient denied at the time. 
Haemodynamically and respiratory stable, he was 
transferred to the psychiatry ward for observation and 
additional diagnostics. Some time after his transfer to 
psychiatry, he reported that he intentionally drank some 
30-year-old poison, because his wife left him a month earlier 
and he wanted to die.
DISCUSSION
The substances found in the powder, gastric lavage, and 
urine were chlormephos and carbofuran. Chlormephos is 
an organothiophosphate soil insecticide, while carbofuran 
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Table 1 Timeline of pathological laboratory findings in our patient with acute OP and carbamate poisioning
Day 1 Day 2 Day 3 Reference values
Hour of measurement (hh:mm) 11:40 17:50 7:50 8:00
ChE (µkat/L) 32 30 31 140 117–317
Lactate (mmol/L) 3.0 4.2 1.5 2.2 0.5–1.8
CRP (mg/L) <3 46 111 0–5
Leucocytes (/mm3) 17.47 12.64 8.95 4–10
Potassium (mmol/L) 2.96 3.18 4.38 3.93 3.5–5.3
CK (µkat/L) 10.29 4.04 0–2.42
ChE – cholinesterase; CRP – C-reactive protein; CK – creatine kinase
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rise in plasma ChE and the patient was gradually extubated 
as clinical and laboratory parameters improved.
In conclusion, even though carbamates and OPs are 
now rare due to stricter regulations, presentation with 
cholinergic symptoms should immediately raise suspicion 
of OP or carbamate poisoning and prompt identification of 
the substance used and corresponding treatment, as 
individuals still keep these products stored at home.
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is a carbamate insecticide, acaricide, and nematicide (11, 
12).
Data on chlormephos toxicity are scarce. Its molecular 
formula is C5H12ClO2PS2. It usually takes the form of a 
colourless liquid that is stable in neutral and weakly acidic 
media at room temperature and solves very poorly in water. 
Following oral administration in rats, it is almost completely 
eliminated by the kidney within 24 h. Absorption and effects 
are believed to be similar to other OP compounds. Its oral 
median lethal dose (LD50) in rats is high, 7 mg/kg (12). 
Carbofuran, on the other hand, is well known, and has an 
even higher LD50 of <50 mg/kg (6). Both substances are 
quite rare in Slovenia now, but individuals might still keep 
their products bought many years ago.
Benzodiazepines should be administered in cholinergic 
syndrome for seizure control as soon as possible, as they 
tend to lose effectiveness with delay of treatment due to 
rapid desensitisation of synaptic GABA A receptors (6, 13). 
If this happens, synthetic neurosteroids such as alphaxolone, 
minaxolone, and ganaxolone may serve as alternative. They 
are currently being studied in preclinical trials on rats 
because of stronger anticonvulsant effects that are not 
limited by GABA desensitisation (13). Atropine and oxime 
therapy were introduced into clinical practice in the 1950s. 
The main idea of using antimuscarinic therapy (atropine) 
is to maintain the heart frequency between 80 and 100 beats 
per minute, raise systolic blood pressure above 80 mmHg, 
and clear bronchial obstruction. Atropine should be started 
with 1–2 mg boluses, and the dose doubled every 5 min 
until the targeted clinical response is achieved. A continuous 
infusion should follow with 10–20 % of the total dose 
administered per hour. Resuscitation fluid should also be 
administered, and when haemodynamic instability persists 
catecholamines are often indicated (1, 3, 4, 6). As our patient 
was not bradycardic and did not show any other signs of 
excessive muscarinic stimulation save for perspiration and 
diarrhoea, we decided against atropine therapy. His blood 
pressure was well controlled with fluid resuscitation and he 
received bronchodilation therapy with inhalations during 
mechanical ventilation.
The use of AChE reactivators is  crucial  in 
organophosphate poisoning as atropine is not effective in 
the neuromuscular synapse. Obidoxime should be started 
as a 250 mg iv bolus over 20–30 minutes. Continuous 
infusion of 30 mg/h should follow for 12–24 h, that is, until 
atropine is not needed (if used) and the patient has been 
extubated (1, 3). However, one should be cautious when 
using oximes in carbamate poisoning. Studying the effects 
of oximes against carbamate toxicity in vitro Wille et al. 
(14) observed that AChE inhibition rates were higher when 
they used an oxime against carbamates carbaryl or propoxur, 
but not when they used it against carbofuran. As we did not 
use atropine, we limited the treatment to 24 h. The patient’s 
condition was continuously improving after the initiation 
of oxime therapy, and we observed no adverse reactions. 
One day after we stopped oxime treatment, we observed a 
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Holinergični sindrom: prikaz primera zastrupitve z organofosfati in karbamati
Holinergični sindrom je pogosta tema na medicinskih fakultetah v zahodnem svetu, ki pa ga redko obravnavamo v klinični 
praksi. Zdravljenje sestoji iz uporabe muskarinskih antagonistov, reaktivacije acetilholinesteraze, nadzora nad epileptičnimi 
napadi in podpornih ukrepov. Predstavljamo primer 52-letnega moškega, ki je poskušal storiti samomor z zaužitjem 
vijoličnega kristalnega prahu, ki se je izkazal za mešanico karbofurana in klormefosa. Ob pregledu smo opažali povečano 
slinjenje in potenje ter prisotnost driske, bradipneje, izgube zavesti in epileptičnih napadov. V laboratorijskih preiskavah 
smo beležili nizke vrednosti plazemske holinesteraze in pričeli zdravljenje z obidoksimom ob podpornem intenzivnem 
zdravljenju. Kasneje smo ga premestili na Oddelek za psihiatrijo za nadaljnjo diagnostiko in zdravljenje. 
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